Antifibrotic drug development · Patent pending

Developing intravenous antifibrotic therapy for advanced liver fibrosis

IRA Med Rx is building the first intravenous formulation of pirfenidone, a proven antifibrotic molecule, for patients with advanced liver disease who need more than oral therapy can offer.

Partner with us Our science

The unmet need

Liver fibrosis is the scarring that drives chronic liver disease toward cirrhosis and liver failure. Despite decades of research, no antifibrotic drug has been approved by the FDA for liver fibrosis.

01

No approved antifibrotic

Treatment today targets the underlying cause, but there is no approved therapy that directly reverses liver scarring.

02

The sickest can't take pills

Hospitalized patients with advanced disease often cannot reliably take oral medication because of nausea, vomiting or confusion.

03

Transplant is limited

Liver transplant remains the last option for end-stage disease, and organs are scarce. New therapies are urgently needed.

Our science

Pirfenidone is an established antifibrotic and anti-inflammatory molecule. We are developing it as an intravenous therapy for controlled, monitored dosing in advanced liver disease.

The liver is both the target organ and the site where pirfenidone is metabolized. Our formulation work focuses on achieving steady, therapeutic exposure through continuous infusion or a sustained-release intravenous form.

  • Oral pirfenidone is FDA-approved for idiopathic pulmonary fibrosis.
  • A prolonged-release oral form is approved for liver fibrosis in Mexico.
  • Clinical studies of oral pirfenidone in advanced liver fibrosis have reported reductions in fibrosis markers.
  • No intravenous form of pirfenidone has yet been tested in humans. That is the gap we are working to close.

Pipeline

Our lead program is intravenous pirfenidone for advanced liver fibrosis. Kidney and lung fibrosis are potential future indications.

ProgramIndicationStage
IV Pirfenidone
Lead program
Advanced liver fibrosis Formulation development
FormulationPreclinicalPhase 1Phase 2Phase 3
IV Pirfenidone Kidney fibrosis Exploratory
IV Pirfenidone Lung fibrosis Exploratory

Partner with us

We are building our team and our network of collaborators. We welcome conversations with:

Academic research partners

Liver fibrosis laboratories and hepatology programs interested in preclinical studies and NIH STTR collaboration.

Development partners

Sterile injectable CDMOs and contract research organizations for formulation, pharmacokinetics and toxicology.

Advisors and investors

Scientific advisors, clinicians and investors who share our goal of bringing a new antifibrotic therapy to patients.

About IRA Med Rx

IRA Med Rx LLC is a founder-led pharmaceutical company focused on antifibrotic therapies. Our mission is to give patients with advanced organ fibrosis a chance to preserve their own organs.

Founder & CEO

Olivia Lee

Olivia founded IRA Med Rx to develop new delivery forms of pirfenidone for patients with fibrotic disease. She leads the company's intellectual property, regulatory and development strategy.

Contact

For partnership, research collaboration or investor inquiries, please reach out.

Emailinfo@iramedrxbio.com

Phone+1 (561) 884-5626

Address1209 Mountain Rd Pl NE, Ste R
Albuquerque, NM 87110, USA